Top Markets
#1 ADO Protocol ADO Protocol +194.43%
#2 Islamic Coin Islamic Coin +155.35%
#3 GoPlus Security GoPlus Security +40.15%
#4 GAIB AID GAIB AID +24.67%
#5 Victoria VR Victoria VR +19.28%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.36%
#7 Wrapped NXM Wrapped NXM +15.19%
#8 Verus Coin Verus Coin +13.65%
#9 Pons Pons +12.72%
#10 o1.exchange o1.exchange +11.86%
Coin of the day
ADO Protocol ADO Protocol
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
TME Pharma N.V. TME Pharma N.V.

TME Pharma N.V.

ALTME
Kedudukan dalam Saham #33517
TME Pharma N.V., a biopharmaceutical company in the clinical development stage... TME Pharma N.V., a biopharmaceutical company in the clinical development stage based in Berlin, Germany, is dedicated to pioneering innovative therapeutic solutions for cancer. The company leverages its unique Spiegelmer platform to advance a pipeline of investigational drug candidates. Its primary oncology asset, NOX-A12, is currently being evaluated in clinical studies as a combination therapy for a range of challenging cancers, including metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. Beyond its cancer-focused efforts, TME Pharma also developed NOX-E36, which has successfully concluded Phase 1/2 clinical trials for diabetic nephropathy. The company has formed a strategic collaboration with Merck Sharp & Dohme Corp. to explore NOX-A12 in combination with Keytruda and two different chemotherapy protocols as a second-line intervention for patients battling metastatic pancreatic cancer. Founded in 1997, the organization adopted its current name, TME Pharma N.V., in July 2022, having previously operated as NOXXON Pharma N.V.
Harga Saham
$0.0794724
Modal Pasaran
$7.49M
Perubahan (1 hari)
4.69%
Perubahan (1 tahun)
-38.28%
Negara
DE
Perdagangan TME Pharma N.V. (ALTME)

Kategori

Healthcare
Pendapatan untuk TME Pharma N.V. (ALTME)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini TME Pharma N.V., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi TME Pharma N.V. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE